ClearNote Health's Avantect Pancreatic Cancer Test Achieves 82.6% Sensitivity in Early Detection
核心洞察
ClearNote Health (搜索)'s Avantect (搜索) Pancreatic Cancer (搜索) Test demonstrates industry-leading detection sensitivity of 82.6% and specificity of 97.5% for patients at elevated risk of pancreatic cancer.
The blood-based test utilizes the company's Virtuoso epigenomics platform, which measures 5-hydroxymethylcytosine (搜索) (5hmC (搜索)) biomarkers in cell-free DNA combined with AI algorithms for early cancer detection.
The test is being incorporated into major international studies including the NHS-led SAFE-D study and the Pancreatic Cancer (搜索) Early Detection (PRECEDE) Consortium for risk-stratified screening.
ClearNote Health (搜索) has announced significant advances in pancreatic cancer (搜索) early detection, with its Avantect (搜索) Pancreatic Cancer Test achieving industry-leading performance metrics of 82.6% sensitivity and 97.5% specificity for patients at elevated risk of this deadly disease. The company will showcase these breakthrough results at two major medical conferences in 2026.
Enhanced Detection Performance Through Epigenomic Profiling
The Avantect (搜索) test leverages ClearNote Health (搜索)'s proprietary Virtuoso epigenomics platform, which measures the epigenomic biomarker 5-hydroxymethylcytosine (搜索) (5hmC (搜索)) in cell-free DNA. According to Chief Science Officer Samuel Levy, PhD, the multi-analyte, multiomic liquid biopsy test combines "5hmC-based epigenomic profiling with other genomic and molecular features, along with state-of-the-art machine learning algorithms" to deliver the enhanced detection performance.
The technology was developed by scientists in the Stephen Quake laboratory at Stanford University and represents a significant advancement in addressing what Chief Medical Officer Jeffrey Venstrom, MD, describes as "one of oncology's most urgent unmet needs."
Target Patient Population and Clinical Applications
The blood-based test is designed for specific high-risk populations, including patients with known genetic predispositions, family history of pancreatic cancer (搜索), or those age 50 or older who have been newly diagnosed with type 2 diabetes (搜索). Dr. Venstrom emphasizes that the test "delivers the sensitivity, specificity, and reliability required to detect pancreatic cancer at its earliest stages."
The approach provides what the company describes as "meaningful context for care discussions" by evaluating multiple cancer-associated signals together, potentially identifying cancers when patients may be more likely to benefit from treatment.
Major International Study Participation
The Avantect (搜索) test has been selected for inclusion in two significant international research initiatives. The NHS in the UK has chosen the test for the Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D) study, described as "one of the world's largest projects evaluating pancreatic cancer (搜索) detection in individuals with new-onset diabetes."
Additionally, the test is being incorporated into the international Pancreatic Cancer (搜索) Early Detection (PRECEDE) Consortium, a global multi-center effort focused on advancing earlier diagnosis and risk-stratified screening for people with familial or genetic risk for pancreatic cancer.
Scientific Presentations and Future Research
ClearNote Health (搜索) will present new clinical data at the American Association for Cancer Research (搜索) (AACR) Annual Meeting 2026 in San Diego (April 17-22) and Digestive Disease Week 2026 in Chicago (May 2-5). Key presentations include an oral presentation by Anna Bergamaschi, PhD, titled "Enhanced Early Detection of Pancreatic Cancer (搜索) Using a Multi-Analyte Liquid Biopsy Approach" and a plenary presentation on blood-based molecular biomarker surveillance.
The company will also present data from studies led by Talia Golan, MD, from Sheba Medical Center, highlighting the potential of cell-free DNA-based epigenomic profiling to differentiate treatment response to platinum and PARP (搜索) inhibitor therapy. This research supports the future development of blood-based biomarkers for predicting treatment response and resistance monitoring.
Platform Technology and Broader Applications
Beyond pancreatic cancer (搜索) detection, ClearNote Health (搜索)'s Virtuoso platform is being utilized by leading biopharma and academic scientists for drug development applications. The platform measures active biological cancer signals and uses advanced AI algorithms to integrate epigenomic data with other genomic information to generate actionable insights for drug response and resistance research.
The company's multi-cancer detection test was recently selected as one of two blood-based technologies for the National Cancer Institute's Vanguard Study, indicating broader recognition of the platform's potential across multiple cancer types.